Terns Pharmaceuticals (TERN) Competitors $3.39 -0.30 (-8.13%) Closing price 03/3/2025 04:00 PM EasternExtended Trading$3.35 -0.04 (-1.18%) As of 03/3/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends TERN vs. PRAX, ADPT, DAWN, ARDX, GPCR, CALT, NTLA, ANIP, AUPH, and ARVNShould you be buying Terns Pharmaceuticals stock or one of its competitors? The main competitors of Terns Pharmaceuticals include Praxis Precision Medicines (PRAX), Adaptive Biotechnologies (ADPT), Day One Biopharmaceuticals (DAWN), Ardelyx (ARDX), Structure Therapeutics (GPCR), Calliditas Therapeutics AB (publ) (CALT), Intellia Therapeutics (NTLA), ANI Pharmaceuticals (ANIP), Aurinia Pharmaceuticals (AUPH), and Arvinas (ARVN). These companies are all part of the "pharmaceutical products" industry. Terns Pharmaceuticals vs. Praxis Precision Medicines Adaptive Biotechnologies Day One Biopharmaceuticals Ardelyx Structure Therapeutics Calliditas Therapeutics AB (publ) Intellia Therapeutics ANI Pharmaceuticals Aurinia Pharmaceuticals Arvinas Terns Pharmaceuticals (NASDAQ:TERN) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends, community ranking and analyst recommendations. Does the MarketBeat Community prefer TERN or PRAX? Praxis Precision Medicines received 7 more outperform votes than Terns Pharmaceuticals when rated by MarketBeat users. Likewise, 75.38% of users gave Praxis Precision Medicines an outperform vote while only 60.00% of users gave Terns Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTerns PharmaceuticalsOutperform Votes4260.00% Underperform Votes2840.00% Praxis Precision MedicinesOutperform Votes4975.38% Underperform Votes1624.62% Which has higher valuation & earnings, TERN or PRAX? Terns Pharmaceuticals has higher earnings, but lower revenue than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Terns Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTerns PharmaceuticalsN/AN/A-$90.21M-$1.18-2.87Praxis Precision Medicines$1.61M389.60-$123.28M-$10.27-3.27 Is TERN or PRAX more profitable? Terns Pharmaceuticals has a net margin of 0.00% compared to Praxis Precision Medicines' net margin of -9,409.22%. Terns Pharmaceuticals' return on equity of -32.76% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Terns PharmaceuticalsN/A -32.76% -31.33% Praxis Precision Medicines -9,409.22%-54.86%-50.52% Which has more volatility and risk, TERN or PRAX? Terns Pharmaceuticals has a beta of -0.34, meaning that its share price is 134% less volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.65, meaning that its share price is 165% more volatile than the S&P 500. Does the media favor TERN or PRAX? In the previous week, Praxis Precision Medicines had 14 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 29 mentions for Praxis Precision Medicines and 15 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 0.29 beat Praxis Precision Medicines' score of 0.06 indicating that Terns Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Terns Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Praxis Precision Medicines 1 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 8 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts rate TERN or PRAX? Terns Pharmaceuticals presently has a consensus target price of $18.30, indicating a potential upside of 439.82%. Praxis Precision Medicines has a consensus target price of $123.80, indicating a potential upside of 269.00%. Given Terns Pharmaceuticals' higher probable upside, equities research analysts clearly believe Terns Pharmaceuticals is more favorable than Praxis Precision Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Praxis Precision Medicines 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Do institutionals & insiders have more ownership in TERN or PRAX? 98.3% of Terns Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 15.1% of Terns Pharmaceuticals shares are owned by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryTerns Pharmaceuticals beats Praxis Precision Medicines on 10 of the 17 factors compared between the two stocks. Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TERN vs. The Competition Export to ExcelMetricTerns PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$287.94M$7.22B$5.82B$8.39BDividend YieldN/A2.79%4.75%3.98%P/E Ratio-2.876.2025.0519.21Price / SalesN/A188.02375.96110.22Price / CashN/A65.6738.0534.58Price / Book0.826.447.334.28Net Income-$90.21M$139.24M$3.19B$247.04M7 Day Performance-9.12%-5.47%-4.36%-4.36%1 Month Performance-22.43%-8.51%-6.01%-5.59%1 Year Performance-53.63%-14.56%11.57%3.39% Terns Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TERNTerns Pharmaceuticals4.5915 of 5 stars$3.39-8.1%$18.30+439.8%-53.6%$287.94MN/A-2.8740PRAXPraxis Precision Medicines2.309 of 5 stars$66.71-10.4%$145.20+117.7%-32.3%$1.24B$2.45M-6.48110Earnings ReportAnalyst ForecastNews CoverageADPTAdaptive Biotechnologies3.5748 of 5 stars$8.42+1.8%$9.10+8.1%+101.0%$1.24B$178.96M-7.72790Positive NewsDAWNDay One Biopharmaceuticals2.5667 of 5 stars$12.18-2.0%$35.71+193.2%-52.7%$1.23BN/A-11.8360Earnings ReportAnalyst RevisionARDXArdelyx4.5864 of 5 stars$5.13+1.4%$9.93+93.5%-45.6%$1.22B$251.85M-32.0690GPCRStructure Therapeutics2.7457 of 5 stars$21.03-11.5%$81.29+286.5%-45.8%$1.20BN/A-28.42136Earnings ReportCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180NTLAIntellia Therapeutics4.536 of 5 stars$11.51-5.4%$48.71+323.2%-71.1%$1.17B$43.09M-2.12600Analyst UpgradeAnalyst RevisionANIPANI Pharmaceuticals4.0117 of 5 stars$55.57-4.1%$77.71+39.8%-13.0%$1.17B$555.46M-101.04600Analyst ForecastHigh Trading VolumeAUPHAurinia Pharmaceuticals2.361 of 5 stars$8.05+1.5%$11.50+42.9%+38.1%$1.15B$220.36M-53.66300ARVNArvinas3.0909 of 5 stars$16.75-5.7%$60.00+258.2%-65.7%$1.15B$263.40M-6.05420 Related Companies and Tools Related Companies Praxis Precision Medicines Competitors Adaptive Biotechnologies Competitors Day One Biopharmaceuticals Competitors Ardelyx Competitors Structure Therapeutics Competitors Calliditas Therapeutics AB (publ) Competitors Intellia Therapeutics Competitors ANI Pharmaceuticals Competitors Aurinia Pharmaceuticals Competitors Arvinas Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TERN) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
